Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Personalized bloodletting could ease life for iron overload patients

NCT ID NCT04779593

Disease control Sponsor: Rennes University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether using a blood marker called transferrin saturation to guide bloodletting (removing blood) improves quality of life in people with HFE haemochromatosis, a genetic condition causing iron buildup. 239 adults already on maintenance bloodletting will be randomly assigned to standard care (guided by ferritin alone) or the new approach. Over two years, researchers will track physical health, joint pain, and fatigue using questionnaires.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
bloodletting (phlebotomy)
What this could lead to
If successful, this could lead to a more personalized bloodletting schedule that improves quality of life for people with haemochromatosis.
What could go wrong
This is a mid-stage study with 239 participants, so results may not apply to everyone. The intervention is already standard care, so major breakthroughs are unlikely.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

239 people

The number who actually took part.

Started

Jul 2021

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * \- Patients treated with iron chelators; * Patients treated with erythroid growth factors (erythropoietin); * Patient with excessive alcohol consumption (\> 20g/day and \> 30 g/day for women and men respectively); * Patients with chronic haematological condition; * Patients having uncontrolled chronic blood loss (of digestive or gynaecological origin); * Patients with chronic kidney failure; * Patients with a diagnosis of cancer or history of cancer in the last year; * Pregnancy or breast feeding. * Patient who are included in another research protocol * Adults legally protected (judicial protection, guardianship, or supervision), persons deprived of their freedom. * with C282Y homozygous HFE hemochromatosis; * having finished the initial phase of HFE hemochromatosis treatment and in maintenance treatment for at least one year; * having signed an informed consent form. Exclusion Criteria: * Patients treated with iron chelators; * Patients treated with erythroid growth factors (erythropoietin); * Patient with excessive alcohol consumption (\> 20g/day and \> 30 g/day for women and men respectively); * Patients with chronic haematological condition; * Patients having uncontrolled chronic blood loss (of digestive or gynaecological origin); * Patients with chronic kidney failure; * Patients with a diagnosis of cancer or history of cancer in the last year; * Pregnancy or breast feeding. * Patient who are included in another research protocol * Adults legally protected (judicial protection, guardianship, or supervision), persons deprived of their freedom.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Haemochromatosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hemochromatosis type 1 hereditary hemochromatosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Haemochromatosis

Contacts and locations

Locations

  • CH Yves le Foll

    Saint-Brieuc, France

  • CH de St Malo

    St-Malo, France

  • CHR Orléans

    Orléans, France

  • CHU Dupuytren

    Limoges, France

  • CHU Rennes

    Rennes, France

  • Centre hospitalier Bretagne Atlantique

    Vannes, France

  • GHBS site du Scorff

    Lorient, France

  • GHRMSA - Hôpital Emile Muller

    Mulhouse, France

  • Hopital Avicenne

    Bobigny, France

  • Hôpital Européen Georges Pompidou

    Paris, 75908, France

  • Hôpital Paul Brousse

    Villejuif, France

  • Hôpital Rangueil

    Toulouse, France